Month: September 2024

Form 8.3 – AXA INVESTMENT MANAGERS: Rightmove Plc

Written by Customer Service on September 3, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: AXA Investment Managers S.A.(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Rightmove plc(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening...

DZS Files Q2 2024 Financial Results

Written by Customer Service on September 3, 2024. Posted in Earnings Releases And Operating Results.

DALLAS, Sept. 03, 2024 (GLOBE NEWSWIRE) — DZS (OTC: DZSI), a developer of Networking and Connectivity solutions enabling broadband everywhere, today announced it has filed Q2 2024 financial results. “The second quarter of 2024 represented a defining period for DZS,” said Charlie Vogt, President and CEO, DZS. “Foremost, we are now current with all restated and delayed Form 10-Q and 10-K filings with the SEC through Q2 2024. From a sales and financial performance perspective, we continue to make progress with our key priorities of 1) creating high-quality, differentiated broadband access solutions for our valued customers, 2) delivering product on-time, 3) optimizing our cost structure and 4) monetizing $75 million of paid inventory. The divestiture of our Asia business in April of this year has enabled us to focus on the North America,...

SPAR Group Enters into Definitive Agreement to be Acquired by Highwire Capital for $2.50 Per Share

Written by Customer Service on September 3, 2024. Posted in Mergers And Acquisitions.

Letter of Intent Previously Announced on June 5, 2024 $2.50 Per Share Merger Consideration Represents a 72% Premium to SPAR Group’s Closing Share Price on August 30AUBURN HILLS, Mich., Sept. 03, 2024 (GLOBE NEWSWIRE) — SPAR Group, Inc. (NASDAQ: SGRP) (“SPAR”, “SPAR Group” or the “Company”), a provider of merchandising, marketing and distribution services, announced today it has entered into a definitive agreement to be acquired by Highwire Capital (“Highwire”), an investment firm focused on transforming businesses through technology. Under the terms of the agreement, which has been unanimously approved by SPAR Group’s Board of Directors, SPAR Group stockholders will receive $2.50 per share in cash, representing a 72% premium over the closing share price on the last trading day before the announcement and a 37.8%...

PharmaCorp Completes Acquisition of a Pharmacy in Western Canada

Written by Customer Service on September 3, 2024. Posted in Mergers And Acquisitions.

SASKATOON, Saskatchewan, Sept. 03, 2024 (GLOBE NEWSWIRE) — PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that, further to its news release dated August 22, 2024, it has completed the acquisition of a 90% interest in a pharmacy (the “Acquired Pharmacy”) located in Western Canada. The acquisition of the Acquired Pharmacy is an arm’s length transaction. The aggregate purchase price for the 90% interest in the Acquired Pharmacy was $2,207,170 and was funded from cash. The Acquired Pharmacy represents PharmaCorp’s second acquisition following the successful completion of its Qualifying Transaction on June 6, 2024, which included the acquisition of a 75% interest in a pharmacy in Saskatoon, Saskatchewan, as well as the previously announced strategic alliance with PharmaChoice Canada Inc. “We...

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Written by Customer Service on September 3, 2024. Posted in Public Companies.

SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference and host 1×1 investor meetings. Date: September 9, 2024Time of Presentation: 7:00 am ESTFormat: Virtual Presentation 1×1 Meetings: Please contact your H.C. Wainwright representative A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register online to...

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

Written by Customer Service on September 3, 2024. Posted in Public Companies.

Authorization expands use of bezisterim in a Phase 2, placebo-controlled, multicenter trial assessing bezisterim’s impact on neurological symptoms associated with long COVID Key milestone reached ahead of schedule, with BioVie on track to receive additional $12.6 million of award from the U.S. Department of Defense and initiate the Phase 2 trial Recent Centers for Disease Control and Prevention survey estimated over 5% of U.S. adults currently have long COVID, and ~3.6 million people reported significantly modifying their activities because of illness1 CARSON CITY, Nev., Sept. 03, 2024 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced...

Compass Therapeutics to Participate in Upcoming Investor Events

Written by Customer Service on September 3, 2024. Posted in Public Companies.

BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September 2024. Details are as follows: H.C. Wainwright 26th Annual Global Investment Conference Location: New York, NY Date: Monday, September 9, 2024 Time: 11:00am ETWebcast Link: https://journey.ct.events/ Cantor Global Healthcare Conference Location: New York, NYDate: Tuesday, September 17, 2024Time: 8:35am ET Webcast Link: https://wsw.com/webcast/cantor Virtual/Replay availability: Presentations will be archived for 90 days on Compass’ Events page. About Compass TherapeuticsCompass Therapeutics,...

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

Written by Customer Service on September 3, 2024. Posted in Public Companies.

– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially Insured Lives – – Increased Coverage and Improved Prior Authorization Processes Make Prescribing NEXLETOL and NEXLIZET Easier for Healthcare Providers – – NEXLETOL and NEXLIZET are the Only Non-Statins FDA Approved to Lower LDL Cholesterol and Reduce Risk of Myocardial Infarction and Coronary Revascularization in Both Primary and Secondary Prevention Patients – ANN ARBOR, Mich., Sept. 03, 2024 (GLOBE NEWSWIRE) — Esperion today announced that NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) have achieved additional coverage on national and large regional formularies since the U.S. Food and Drug Administration’s (FDA)...

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Written by Customer Service on September 3, 2024. Posted in Public Companies.

HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces that management will be participating in the following investor and industry conferences during the month of September:H.C. Wainwright 26th Annual Global Investment Conference, September 9-11, 2024, at the Lotte New York Palace Hotel. Management will be holding one-on-one meetings with investors and will deliver a company presentation. The recorded presentation will be available on demand beginning Monday, September 9th at 7:00am Eastern time on the Investors section of Processa’s website and here. European Society for Medical Oncology (ESMO) Congress 2024, September 13-17, 2024, in Barcelona. Management will be holding meetings with clinicians, researchers, industry key opinion leaders and potential partners.About Processa Pharmaceuticals,...

LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Written by Customer Service on September 3, 2024. Posted in Public Companies.

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 03, 2024 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 26th Annual Global Investment Conference. Presentation DetailsFormat: Fireside ChatDate: Monday, September 9, 2024Time: 3:30 PM ET A webcast of the presentation can be accessed under the “Events” tab on the investor relations section of the LAVA Therapeutics website at https://ir.lavatherapeutics.com/news-events/events. The replay will be archived for 90 days following the presentation date. About LAVA Therapeutics LAVA Therapeutics N.V. is...

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Month: September 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals